Patents Represented by Attorney James L. Rowe
  • Patent number: 5366996
    Abstract: A therapeutic process for treating anemias in primates, including man, particularly those anemias of genetic origin including sickle-cell anemia, which comprises administering to an anemic primate an amount of a polyhydroxy benzoic, mandelic or phenylacetic acid derivative as specified at a dose level sufficient to increase fetal hemoglobin.
    Type: Grant
    Filed: December 7, 1992
    Date of Patent: November 22, 1994
    Inventors: Howard L. Elford, Bartholomeus van't Riet
  • Patent number: 5350770
    Abstract: A therapeutic process for treating septic shock comprising the administration of a polyhydroxy-substituted benzamide or phenylacetamide derivative to a human suffering from, or in danger of contracting, septic shock.
    Type: Grant
    Filed: July 28, 1992
    Date of Patent: September 27, 1994
    Inventors: Howard L. Elford, Bartholomeus van't Riet
  • Patent number: 5183828
    Abstract: Polyhydroxy-substituted benz, phenylacet and mandelamidines, amidates, amidoximes and hydroxyamidoximes--ribonucleotide reductase inhibitors, and free radical scavengers.
    Type: Grant
    Filed: July 20, 1990
    Date of Patent: February 2, 1993
    Inventors: Bartholomeus van't Riet, Howard L. Elford, Galen L. Wampler
  • Patent number: 4942253
    Abstract: Polyhydroxy-substituted benz, phenylacet and mandelamidines, amidates, amidoximes and hydroxyamidoximes--ribonucleotide reductase inhibitors, and free radical scavengers.
    Type: Grant
    Filed: September 15, 1986
    Date of Patent: July 17, 1990
    Inventors: Bartholomeus van't Riet, Howard L. Elford, Galen L. Wampler
  • Patent number: 4652554
    Abstract: 1-(2-O-Nitro-.beta.-D-arabinofuranosyl)cytosine and salts, anti-leukemics.
    Type: Grant
    Filed: February 22, 1982
    Date of Patent: March 24, 1987
    Assignee: St. Jude Children's Research Hospital
    Inventor: Tek L. Chwang
  • Patent number: 4626591
    Abstract: A process for preparing 1-alkyl-6-oxodecahydroquinolines in 5 steps--a quaternization, hydrogenation, two organometallic reductions and hydrolysis of the thus formed enol ether--from 6-alkyloxyquinoline and intermediates useful therein.
    Type: Grant
    Filed: April 19, 1985
    Date of Patent: December 2, 1986
    Assignee: Eli Lilly and Company
    Inventor: John M. Schaus
  • Patent number: 4623659
    Abstract: Polyhydroxy-substituted benz, phenylacet and mandelamidines, amidates, amidoximes and hydroxyamidoximes--ribonucleotide reductase inhibitors, and free radical scavengers.
    Type: Grant
    Filed: May 23, 1983
    Date of Patent: November 18, 1986
    Inventors: Bartholomeus van't Riet, Howard L. Elford, Galen L. Wampler
  • Patent number: 4622398
    Abstract: 2-Permissibly-substituted-6-dialkylaminotetrahydroquinazolines, receptor agonists.
    Type: Grant
    Filed: June 24, 1985
    Date of Patent: November 11, 1986
    Assignee: Eli Lilly and Company
    Inventor: Bennett C. Laguzza
  • Patent number: 4613620
    Abstract: Novel oxiodinium and thiaiodinium compounds having a superior inhibitory effect against micro-organisms coupled with outstanding stability and low toxicity are described.
    Type: Grant
    Filed: February 13, 1981
    Date of Patent: September 23, 1986
    Assignee: Eli Lilly and Company
    Inventor: William N. Cannon
  • Patent number: 4605649
    Abstract: 2,4-Difluoro-.beta.-estradiol, 2-fluoro-.beta.-estradiol, and related fluoro estrogens used to treat estrogen-deficiency states in human females with genetic predisposition to cancer of estrogen-sensitive tissues.
    Type: Grant
    Filed: March 28, 1984
    Date of Patent: August 12, 1986
    Inventor: Joachim G. Liehr
  • Patent number: 4596676
    Abstract: Bifunctional ester derivatives at C-4 carbon of dimeric indole-dihydroindole alkaloids; e.g., VLB 4-hemisuccinate.
    Type: Grant
    Filed: March 26, 1984
    Date of Patent: June 24, 1986
    Assignee: Lilly Industries Limited
    Inventor: George J. Cullinan
  • Patent number: 4584404
    Abstract: Selective biogenic amine uptake inhibitors, 3-substituted phenyloxy-3-phenylpropyldimethylamines.
    Type: Grant
    Filed: October 24, 1983
    Date of Patent: April 22, 1986
    Assignee: Eli Lilly and Company
    Inventors: Bryan B. Molloy, Klaus K. Schmiegel
  • Patent number: 4576959
    Abstract: (.+-.)-4-substitutedamino-6-substituted-1,3,4,5-tetrahydrobenz[c,d]indoles and pharmaceutically acceptable salts thereof, useful as anti depressants.
    Type: Grant
    Filed: February 1, 1985
    Date of Patent: March 18, 1986
    Assignee: Eli Lilly and Company
    Inventor: Michael E. Flaugh
  • Patent number: 4567266
    Abstract: A 1-substituted-3-permissibly-substituted-6 (or 7)-oxodecahydroquinoline is converted to the corresponding 7 (or 6)-formyl derivative. The 6-oxo-7-formyl compound, upon treatment with hydrazine, is cyclized to a tautomeric mixture of 5-substituted-7-permissibly-substituted-4,4a,5,6,7,8,8a,9-octahydro-1H(and 2H)-pyrazolo[3,4-g]quinolines.
    Type: Grant
    Filed: August 2, 1984
    Date of Patent: January 28, 1986
    Assignee: Eli Lilly and Company
    Inventor: John M. Schaus
  • Patent number: 4565871
    Abstract: Trans-(.+-.) or trans-(-)-2,4-permissibly-substituted-6-alkyl or allyl octahydropyrimido[4,5-g]quinolines and related compounds, ultraviolet light absorbers.
    Type: Grant
    Filed: December 11, 1984
    Date of Patent: January 21, 1986
    Assignee: Eli Lilly and Company
    Inventors: Cynthia L. Nicholas, Edmund C. Kornfeld, John M. Schaus
  • Patent number: 4563461
    Abstract: Method of blocking 5HT.sub.2 without effect on alpha receptors with 1-loweralkyl-6-methyl-8.beta.-(hydroxy)alkoxy carbonyl-5R-ergolines.
    Type: Grant
    Filed: March 10, 1983
    Date of Patent: January 7, 1986
    Assignee: Eli Lilly and Company
    Inventors: Marlene L. Cohen, Ray W. Fuller
  • Patent number: 4558053
    Abstract: Stable, biologically available, orally active 1,5-naphthalenedisulfonate salt of vinzolidine.
    Type: Grant
    Filed: December 21, 1983
    Date of Patent: December 10, 1985
    Assignee: Eli Lilly and Company
    Inventors: Stanislaw Rolski, Ralph R. Pfeiffer
  • Patent number: 4552888
    Abstract: Ethers of ascorbic and isoascorbic acid and ketals and acetals thereof, angiogenesis inhibitors.
    Type: Grant
    Filed: September 28, 1983
    Date of Patent: November 12, 1985
    Assignee: Eli Lilly and Company
    Inventors: Gary A. Koppel, Russell L. Barton, Jesse R. Bewley, Stephen L. Briggs, Joseph W. Parton
  • Patent number: 4552956
    Abstract: Pyrazolo, pyrimido and thiazolo[1,4]benzoxazines, useful as dopamine agonists.
    Type: Grant
    Filed: August 15, 1984
    Date of Patent: November 12, 1985
    Assignee: Eli Lilly and Company
    Inventors: Richard N. Booher, Edmund C. Kornfeld
  • Patent number: 4544752
    Abstract: 3-Phenyl (or meta or para-substituted phenyl)-4-permissibly substituted-5-isothiazolecarboxylic acids, salts, esters and simple amides, used to lower uric acid levels in mammals.
    Type: Grant
    Filed: June 6, 1983
    Date of Patent: October 1, 1985
    Assignee: Eli Lilly and Company
    Inventors: James R. Beck, Robert P. Gajewski, Ronald E. Hackler